Analyst Price Target is $14.25
▲ +192.61% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $14.25, with a high forecast of $19.00 and a low forecast of $10.00. The average price target represents a 192.61% upside from the last price of $4.87.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Prelude Therapeutics. This rating has held steady since October 2021, when it changed from a Hold consensus rating.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.